SynAct Pharma AB

OM:SYNACT Stock Report

Market Cap: SEK 1.1b

SynAct Pharma Past Earnings Performance

Past criteria checks 0/6

SynAct Pharma's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 40.6% annually.

Key information

-8.04%

Earnings growth rate

4.55%

EPS growth rate

Biotechs Industry Growth0.71%
Revenue growth raten/a
Return on equity-61.83%
Net Marginn/a
Next Earnings Update03 Nov 2026

Recent past performance updates

Recent updates

Analysis Article • May 28

Is SynAct Pharma (STO:SYNACT) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Feb 12

Is SynAct Pharma (STO:SYNACT) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 09

We're Keeping An Eye On SynAct Pharma's (STO:SYNACT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 18

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 04

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 18

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. By way of example, SynAct Pharma...
Analysis Article • Sep 03

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, SynAct Pharma...
Analysis Article • Apr 07

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, SynAct Pharma...

Revenue & Expenses Breakdown

How SynAct Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:SYNACT Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-1063579
31 Mar 260-1123387
31 Dec 250-1113286
30 Sep 250-1062788
30 Jun 250-912479
31 Mar 250-822963
31 Dec 240-824049
30 Sep 240-1554046
30 Jun 240-1664548
31 Mar 240-1914869
31 Dec 230-21645105
30 Sep 230-15648116
30 Jun 230-14844115
31 Mar 230-12942100
31 Dec 220-993670
30 Sep 220-953369
30 Jun 220-893164
31 Mar 220-782263
31 Dec 210-691660
30 Sep 210-521546
30 Jun 210-411237
31 Mar 210-351029
31 Dec 200-27923
30 Sep 200-29-132
30 Jun 200-24125
31 Mar 200-23620
31 Dec 190-241015
30 Sep 190-20230
30 Jun 190-23260
31 Mar 190-24300
31 Dec 180-23622
30 Sep 180-23280
30 Jun 180-19230
31 Mar 180-15180
31 Dec 170-15180
30 Sep 170-23250
31 Dec 160-21220

Quality Earnings: SYNACT is currently unprofitable.

Growing Profit Margin: SYNACT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SYNACT is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.

Accelerating Growth: Unable to compare SYNACT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SYNACT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).

Return on Equity

High ROE: SYNACT has a negative Return on Equity (-61.83%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:28
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynAct Pharma AB is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Carnegie
Jyoti PrakashEdison Investment Research
Carl RamaniusRedeye